EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

This study is evaluating a type of targeted radiation therapy called radioligand therapy (RLT) — a treatment that delivers radiation directly to prostate cancer cells using a molecule that attaches to a protein called PSMA — in men with advanced prostate cancer that has stopped responding to hormone therapy. **You may be eligible if...** - You are a male 18 years or older - You have prostate cancer confirmed by biopsy or imaging - Your cancer is metastatic and castration-resistant (has spread and no longer responds to hormone therapy) - You have already received at least one taxane chemotherapy and one hormone-blocking drug (unless medically unsuitable) - Your cancer is still progressing (rising PSA, new bone lesions, or tumor growth) - Your PSMA expression on imaging is significant - Your testosterone levels are very low (castration levels) **You may NOT be eligible if...** - You have not had prior hormone-blocking therapy - You do not have significant PSMA expression on a scan - Your overall health is too poor (ECOG >2) - Your cancer is progressing in ways that don't meet study criteria Talk to your doctor to see if this trial is right for you.